Abstract
Yttrium-90 (Y90) radioembolization has historically been applied in a lobar fashion when treating patients with metastatic disease to the liver due to the multifocal presentation of these patients. We hypothesize that segmental Y90 delivery, routinely used to treat HCC, can be safely and effectively utilized to treat oligometastatic secondary hepatic malignancies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
